Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

All

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 5 - LDE225 for patients with PTCH1 and SMO mutated tumors

Researchers want to know if LDE225 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a PTCH1 and/or SMO activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Johnson

An Open-label, Randomized Phase IIb/III Active Control Study of Second-line HyperAcute®-Lung (tergenpumatucel-L) Immunotherapy versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer

The purpose of this study is to compare the effects, good and/or bad, of standard of care therapy (docetaxel alone) versus HyperAcute®-Lung (HAL) immunotherapy to find out which treatment is better.

Status: Accepting New Patients
Principal Investigator: Patel

Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 3 - MEK162 for Patients with RAS/RAF/MEK Activated Tumors Local

The purpose of this clinical trial is to study if MEK162 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a RAS/RAF/MEK activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Johnson

Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

The purpose of this study is to compare the effects, good and/or bad, of veliparib when combined with the standard commonly-used drugs (cisplatin and etoposide) on patients and their lung cancer.

Status: Accepting New Patients
Principal Investigator: Johnson

Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 4 - LGX818 for Patients with BRAFC600 Mutated Tumors

Researchers want to know if LGX818 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a BRAFV600 activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Johnson

Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 - Dovitinib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including Tumors with Mutations or Translocations of FGFR, PDGFR, VEGF, CKIT, FLT3, CSFR1, TRK and RET

Researchers want to know if dovitinib (TKI258) is safe and has beneficial effects in people who have different tumor types (cancer) and/or blood malignancies whose disease progressed after standard treatment.

Status: Accepting New Patients
Principal Investigator: Johnson

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Petrich

A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer

The purpose of this study is to test the safety and tolerability of the research study drug, MK-3475, and to test how effective it is compared to the standard of care, docetaxel, for non-small cell lung cancer.

Status: Accepting New Patients
Principal Investigator: Johnson

A Phase IB Open-Label, Multi-Center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYl719 in Adult Patients with Selected Advanced Solid Tumors

The main purpose of this study is to see what effect, good and/or bad, MEK162 and BYL719 given together has on certain advanced solid tumors.

Status: Accepting New Patients
Principal Investigator: Johnson

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to find out what effects, good and/or bad, the treatments used in this study have on patients and their locally advanced, non-operable lung cancer with specific gene alterations (EGFR mutation or ALK rearrangement).

Status: Accepting New Patients
Principal Investigator: Patel

Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC)

The purpose of this study is to compare the effects of radiation given to the brain after chemotherapy with radiation to the brain, chest and up to 3 other sites that did not completely respond to treatment after chemotherapy to find out which is better.

Status: Accepting New Patients
Principal Investigator: Marymont

A Phase II, Multicenter, Single-Arm Study of MPDL3280a in Patients with PD-L1–Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to look at the effects, good or bad, of MPDL3280A on patients and their non-small cell lung cancer (NSCLC).

Status: Accepting New Patients
Principal Investigator: Johnson

A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)

The purpose of this study is to evaluate the safety (side effects) and tolerability (how participants handle the side effects) of AT13387 when administered in combination with crizotinib in treating non-small cell lung cancer (NSCLC).

Status: Accepting New Patients
Principal Investigator: Patel

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Hitsman

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

The primary purpose of this research is to find out the best maintenance therapy for patients with advanced stage non-small cell lung cancer.

Status: Accepting New Patients
Principal Investigator: Johnson

A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation

The purpose of this study is to find out what effects the addition of L-BLP25 vaccine and bevacizumab, to the commonly used treatment of paclitaxel, carboplatin, and thoracic radiation therapy (radiation to the chest) has on lung cancer.

Status: Accepting New Patients
Principal Investigator: Patel

Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

There are 2 parts to this study (phase II and phase III). The part of the study in which a participant is enrolled depends on the timing of starting in the study. The purpose of the phase II part of the study is to treat the cancer that has spread to a participant's spine, and is causing pain, with image-guided radiosurgery/SBRT. The purpose of phase III is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects.

Status: Accepting New Patients
Principal Investigator: Kalapurakal

A Phase II Trial of Bevacizumab in Patients with Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy

The purpose of this study is to see what effect bevacizumab, the drug being tested, will have on brain disease from solid tumor cancers. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer.

Status: Accepting New Patients
Principal Investigator: Kumthekar

last updated: Tue - September 30, 2014 - 05:58 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.